Trump's nomination of vaccine skeptic Robert F. Kennedy Jr. as HHS chief sparks unease in biotech and pharma sectors, raising concerns about regulatory stability and investment.
Trump's nomination of vaccine skeptic Robert F. Kennedy Jr. as HHS chief sparks unease in biotech and pharma sectors, raising concerns about regulatory stability and investment.